Conmed Corp

CNMD remains in a Stage 2 advancing phase with a strong breakout and rising EMA support. An active Lockout Rally signals forced participation, overriding typical overbought concerns and justifying immediate buy-side engagement. Continuation participation now captures urgent repricing dynamics while relying on the EMA structure. Caution remains due to extreme overbought levels and the potential for a pullback.

• ↑Q1 revenue of $321.3M (+2.9% YoY) and 2025 guidance of $1.35–1.378B
• ↑AirSeal and BioBrace platforms expected to drive high single-digit to low double-digit growth
• ↓Q1 adjusted net income $29.6M (down 8.5% YoY) highlights cost and segment exit impacts